Phase II study of gemcitabine (G), trastuzumab (H), and pertuzumab (P) for HER2-Positive metastatic breast cancer (MBC) after prior HP- or TDM/P-based therapy.

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Safety of Herceptin monotherapy administered on a 3-weekly schedule: Preliminary data from a phase II study in women with HER2-positive metastatic breast cancer

European Journal of Cancer ◽

10.1016/s0959-8049(02)80299-4 ◽

2002 ◽

Vol 38 (11) ◽

pp. S95

Author(s):

J Baselga

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Preliminary Data ◽

Phase Ii Study ◽

Metastatic Breast ◽

Weekly Schedule ◽

SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab (with or without letrozole in ER+) in previously trastuzumab-pretreated, postmenopausal patients with HER2-positive metastatic breast cancer

Annals of Oncology ◽

10.1093/annonc/mdx365.084 ◽

2017 ◽

Vol 28 ◽

pp. v106-v107 ◽

Cited By ~ 3

Author(s):

P. Villagrasa Gonzalez ◽

A. Prat ◽

M. Oliveira ◽

L. de la Pena ◽

X. Gonzalez ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

232 Final Results of a Phase II Study of the Combination of Oral Vinorelbine (NVBo), Capecitabine (X) and Trastuzumab (H) in HER2-positive Metastatic Breast Cancer (MBC)

European Journal of Cancer ◽

10.1016/s0959-8049(12)70300-3 ◽

2012 ◽

Vol 48 ◽

pp. S110

Author(s):

L. Petruzelka ◽

V. Ganju ◽

P.F. Conte ◽

N. Tubiana-Mathieu ◽

F. Majois ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Her2 Positive ◽

Oral Vinorelbine

Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II study

Breast Cancer Research and Treatment ◽

10.1007/s10549-017-4203-y ◽

2017 ◽

Vol 163 (3) ◽

pp. 507-515 ◽

Cited By ~ 3

Author(s):

Konstantinos Tryfonidis ◽

◽

S. Marreaud ◽

H. Khaled ◽

B. De Valk ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Extracellular Domain ◽

Cardiac Safety ◽

Her2 Positive ◽

Serial Serum

Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy

Annals of Oncology ◽

10.1093/annonc/mdx365.015 ◽

2017 ◽

Vol 28 ◽

pp. v81

Author(s):

N.M. Iyengar ◽

L.M. Smyth ◽

D. Lake ◽

A. Gucalp ◽

J.C. Singh ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Abstract OT1-1-13: A phase II study with lead-in safety cohort of cabazitaxel plus lapatinib as therapy for patients with HER2-positive metastatic breast cancer (MBC) and intracranial metastases

10.1158/0008-5472.sabcs13-ot1-1-13 ◽

2013 ◽

Author(s):

DA Yardley ◽

JD Hainsworth ◽

E Hamilton ◽

LL Hart ◽

M Shastry ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Her2 Positive ◽

Intracranial Metastases

Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy

Annals of Oncology ◽

10.1093/annonc/mdw365.49 ◽

2016 ◽

Vol 27 ◽

pp. vi84 ◽

Cited By ~ 1

Author(s):

N.M. Iyengar ◽

L. Smyth ◽

D. Lake ◽

A. Gucalp ◽

J. Singh ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab pre-treated patients with Her2-positive metastatic breast cancer - E-Vita -

Annals of Oncology ◽

10.1093/annonc/mdw365.52 ◽

2016 ◽

Vol 27 ◽

pp. vi85

Author(s):

J. Bischoff ◽

J. Barinoff ◽

C. Mundhenke ◽

D. Bauerschlag ◽

S.D. Costa ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Her2 Positive ◽

Randomized Phase Ii

A multinational phase II study of Navelbine (N) and Herceptin (H) as first-line therapy for patients with HER2-positive metastatic breast cancer (HER2+ MBC)

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(04)90846-4 ◽

2004 ◽

Vol 2 (3) ◽

pp. 127 ◽

Cited By ~ 1

Author(s):

M Untch ◽

S Kahlert ◽

L Petruzelka ◽

M Martin ◽

V Guillem-Porta ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

First Line ◽

Her2 Positive ◽

First Line Therapy ◽

Line Therapy

Phase II study of the combination of oral vinorelbine (NVBo), capecitabine (X), and trastuzumab (H) in HER2-positive, metastatic breast cancer (MBC): Recent analysis of the results with a median follow-up of 44 months.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.1077 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 1077-1077 ◽

Cited By ~ 4

Author(s):

L. B. Petruzelka ◽

V. Ganju ◽

D. Becquart ◽

P. F. Conte ◽

N. Tubiana-Mathieu ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Recent Analysis ◽

Her2 Positive ◽

Oral Vinorelbine